Compare AIIO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIIO | PRTA |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United Arab Emirates | Ireland |
| Employees | 29 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.1M | 449.7M |
| IPO Year | N/A | 2013 |
| Metric | AIIO | PRTA |
|---|---|---|
| Price | $3.20 | $8.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 886.9K | 538.7K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.69 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $7.50 |
| 52 Week High | $9.20 | $11.80 |
| Indicator | AIIO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | N/A |
| Support Level | $2.60 | N/A |
| Resistance Level | $4.96 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 51.08 | 0.00 |
Robo.ai Inc is a decentralized, AI-powered intelligent mobility platform that integrates smart vehicles, robotics, and blockchain technologies. The company is developing an AI-NAS ecosystem focused on delivering a passenger-centric platform by combining hardware and software, leveraging onboard computing, and offering an open cloud environment. Its product portfolio includes MUSE, a full-sized autonomous electric SPV; GHIATH, a purpose-built vehicle for public services and law enforcement developed in collaboration with Dubai Police; and Astra, an autonomous logistics vehicle. It also offers other vehicle models such as NWONE (SUV), Rabdan One (SUV), and Rabdan Seven (MPV) in the UAE through the SKD model. The company operates across the USA, UAE, and Mainland China.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.